Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederinvestors.amgen.com
Amgen Inc. News Releases
Get the latest updates from Amgen Inc. News Releases directly as they happen.
Follow now 182 followers
Latest posts
Last updated about 4 hours ago
AMGEN TO PRESENT AT THE BANK OF AMERICA MERRILL LYNCH GLOBAL HEALTHCARE CONFERENCE
about 4 hours ago
THOUSAND OAKS, Calif. , May 9, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will...
AMGEN REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS
8 days ago
THOUSAND OAKS, Calif. , May 1, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today...
AMGEN ANNOUNCES WEBCAST OF 2025 FIRST QUARTER FINANCIAL RESULTS
11 days ago
THOUSAND OAKS, Calif. , April 28, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today...
AMGEN ANNOUNCES $900 MILLION MANUFACTURING EXPANSION, CREATION OF 350 NEW JOBS IN OHIO
14 days ago
Total Investment in the State to Exceed $1.4 Billion , 750 U.S...
IMDELLTRA® DEMONSTRATED SUPERIOR OVERALL SURVIVAL IN SMALL CELL LUNG CANCER
28 days ago
First Global Phase 3 Trial Showing Substantial Survival Advantage Over Chemotherapy, for...
UPLIZNA® (INEBILIZUMAB-CDON) IS NOW THE FIRST AND ONLY FDA-APPROVED TREATMENT FOR IGG4-RELATED DISEASE
about 1 month ago
Breakthrough CD19+ B-Cell Targeted Therapy Delivered an 87% Reduction in the Risk...
UPLIZNA® (INEBILIZUMAB-CDON) SIGNIFICANTLY IMPROVES GENERALIZED MYASTHENIA GRAVIS SYMPTOMS IN ACETYLCHOLINE RECEPTOR AUTOANTIBODY-POSITIVE PATIENTS OVER 52 WEEKS
about 2 months ago
Patients Reported Improvement in Ability to Conduct Daily Activities with Twice-Yearly Dosing...
AMGEN AND KYOWA KIRIN PROVIDE TOP-LINE RESULTS FROM ROCATINLIMAB PHASE 3 IGNITE STUDY IN ADULTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS
2 months ago
Ongoing Studies are Evaluating Long-Term Maintenance and Durability THOUSAND OAKS, Calif...
AMGEN ANNOUNCES 2025 SECOND QUARTER DIVIDEND
2 months ago
THOUSAND OAKS, Calif. , March 4, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today...
POSITIVE RESULTS FROM TEZSPIRE® (TEZEPELUMAB-EKKO) PHASE 3 WAYPOINT TRIAL HIGHLIGHT RAPID, SUSTAINED EFFECT IN CHRONIC RHINOSINUSITIS WITH NASAL POLYPS
2 months ago
Significantly Reduced Nasal Congestion, Polyp Size and Nearly Eliminated Need for Surgery...
AMGEN TO PRESENT AT THE 45TH ANNUAL TD COWEN HEALTH CARE CONFERENCE
2 months ago
THOUSAND OAKS, Calif. , Feb. 28, 2025 /PRNewswire/ -- Amgen (NASDAQ: AMGN)...
AMGEN TO PRESENT AT CITI'S 2025 VIRTUAL ONCOLOGY LEADERSHIP SUMMIT
3 months ago
THOUSAND OAKS, Calif. , Feb. 14, 2025 /PRNewswire/ -- Amgen (NASDAQ: AMGN)...